The Economist. Expresses its satisfaction with the publication of the latest statement document of the European Crohn's Disease and Colitis Organization (ECCO) on the use of biosimilars to treat inflammatory bowel disease, which endorses the use of biosimilar infliximab instead of infliximab. 1
recently published
Horizon scanning
Jan 31 2024
Early Treatment: the role of biosimilars
18 2023 December
